Latest Healius News & Updates

See the latest news and media coverage for Healius. We track all announcements, press releases, and industry mentions in real time, all in one place.

Healius

Pathology and diagnostic services provider

healius.com.au

Headquarters: Sydney, Australia
Company type: Public company
Number of employees: 5,000–10,000
Industry: Healthcare Facilities & Services

Last updated Today

Latest news about Healius

In short: Healius downgraded its earnings outlook and progressed a strategic review, including the potential sale of its Agilex Biolabs division.

Company announcements

June 26 Healius

Healius transitions pathology arrangements with Ramsay Health Care subsidiaries

The new national framework covers thirteen hospitals and is expected to generate approximately $45m annual revenue.

May 13 Healius

Healius announces FY 2026 trading update and strategic review

Group EBITDA expected between $259m and $264m; exploring sale of Agilex Biolabs; Federal Budget offers no new pathology funding.

March 31 Healius

Healius Limited reports John Mattick's final director's interest notice

John Mattick ceased as director on 31 March 2026. He holds 4,136 ordinary shares directly and interests in 250,181 shares indirectly.

February 18 Healius

Healius announces 1H 2026 results

Group revenue rises 3.8% to $688.1M, EBITDA up 13.1% to $122.2M, EBIT $7.9M from prior loss. Pathology revenue up 3.5%, Agilex up 16%.

Media coverage

June 29 AFR

PE, strategics line up for Healius' Agilex as IMs hit inboxes

Sellside adviser UBS issued more than 30 investment memorandums over the weekend and called for non-binding offers before the end of July.

May 23 The Globe and Mail

Macquarie Group Ceases to Be Substantial Holder in Healius Limited

Start a conversation with TipRanks' trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds...

May 16 The Globe and Mail

Healius Limited (PGZ) Gets a Sell from Jarden

Jarden analyst Steven Wheen maintained a Sell rating on Healius Limited yesterday and set a price target of A$0.47. The company's shares closed yesterday at...

May 15 Yahoo Finance

Is Healius (ASX:HLS) Using Agilex Sale Talks To Reframe Its Labour-Intensive Pathology Strategy?

In May 2026, Healius Limited (ASX:HLS) said it had engaged UBS Securities Australia to explore a potential sale of its standalone Agilex Biolabs business after...

Never miss news about Healius

Track Healius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Healius competitors & trending companies

Browse news for competitors to Healius and other trending companies.